A national prospective observational study in breast cancer patients with central nervous system involvement in the UK
Breast cancer is the second most common primary tumour to metastasise to the brain. Brain metastases is a growing problem among patients living with metastatic BC, particularly for patients with triple negative and human epidermal growth factor receptor 2 (HER2)-positive disease, and is associated with significant morbidity and mortality.
PRIMROSE aims to use the trainee collaborative model to establish an observational prospective database that will aim to prospectively register all patients with newly diagnosed CNS involvement secondary to BC in the UK, and to collect data relating to presentation, diagnosis, management and outcome.
The overarching objectives include
1. To define the incidence of metastatic BC involving the central nervous system in the UK.
2. To prospectively describe the current practice in diagnosis, staging and management of metastatic disease in the central nervous system in relation to national and international guidelines, including the NICE guidelines for the management of brain metastases in adults (NG99, July 2018), EANO (2017) and the NCCN guidelines (Version 1.2018 Central Nervous System Cancers).
3. To evaluate the outcomes of patients treated for BC related central nervous system metastases in the UK
4. To generate data to help guide best practice guidelines in the future.
5. To inform and help in the development of potential prospective studies and clinical trials.
Who might be particularly interested?
Breast care nurses
Medical Oncology trainees
Clinical Oncology trainees
...but this isn't exclusive. If you'd like to find out more, then get in touch!
PRIMROSE trainee leads: Dr Vinton Cheng
Dr Hayley McKenzie
Dr Amy Kwan
Senior lead: Prof Carlo Palmieri